



Applicant's Docket No. MPI00-408P1RM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Kapeller-Liberman, Rosana et al.
Application No.: 10/001,227 Group No.: 1647
Filed: November 30, 2001 Examiner: Jon McClelland Lockard
For: METHOD OF USING 18903 TO TREAT PAIN AND PAIN-RELATED DISORDERS.

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

Responsive to the Restriction Requirement dated August 4, 2004, the claims of Group VI (claims 22, 24 and 31 (in part)), drawn to a method of identifying a compound which binds/modulates COE-2 polypeptides, are elected for prosecution without traverse. Applicants note, however, that group VI should include claims 23, 24 and 31 (in part) rather than claims 22, 24 and 31 (in part), as claim 22 is directed to kits. Applicants hereby reserve the right to traverse the above restriction with respect to non-elected Groups I-V and VII-IX in this or subsequent applications.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

☒ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Addressee" Mailing Label No. _____

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office.


Signature

Sean Hunziker

Date: September 1, 2004

(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

This paper is being filed timely and no extensions of time are required. In the event any extensions of time are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.


Entry of the remarks made herein is respectfully requested.

September 1, 2004

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By



Mario Cloutier

Limited Recognition Under 37 C.F.R. §10.9(b)

40 Lansdowne Street

Cambridge, MA 02139

Telephone – (617) 577-3522

Facsimile – (617) 551-8820